Browse Studies — Arctuva

Phase 3

A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation

The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myel…

Graft-versus-host Disease (GVHD)

Estimated

~$10 – $8,750

Incyte CorporationNCT06615050

Phase 2

A Phase II Randomized Trial to Optimize GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation in Older Adults With Hematological Malignancies: the PROMISE Trial

This study will compare post-transplant health-related quality of life following the use of standard versus attenuated dose of post-transplant cyclophosphamide…

Hematological MalignanciesGraft-versus-Host Disease (GVHD)

Estimated

~$10 – $6,250

University of NebraskaNCT06799195

Phase 2

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) With Low-Dose Post-Transplant Cyclophosphamide for Prophylaxis of Graft-versus-Host Disease in Hematological Malignancies

This Phase 2, single-arm, open-label study aims to evaluate the safety and efficacy of low-dose (25 mg/kg) post-transplant cyclophosphamide (PTCy) for prophyla…

Graft-versus-Host Disease (GVHD)Hematologic MalignanciesAllogeneic Stem Cell Transplantation

Estimated

~$10 – $6,250

Milton S. Hershey Medical CenterNCT06926595